{"eventGroups":[{"deathsNumAffected":5,"deathsNumAtRisk":20,"description":"Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant\n\nCyclophosphamide: 14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)\n\nFludarabine: 30 mg/m2 daily for 5 days\n\nTotal Body Irradiation: 200 centigray (cGy) for one day (day -1)\n\nTacrolimus: 1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.\n\ncellcept: dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.\n\ng-csf: 5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \\> 1000/mcL for 3 days.\n\nPeripheral Blood Transplant: cell dose goal: \\< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight","id":"EG000","otherNumAffected":16,"otherNumAtRisk":20,"seriousNumAffected":3,"seriousNumAtRisk":20,"title":"Johns Hopkins' Conditioning Regimen"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":20,"numEvents":18}],"term":"Anorexia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":20,"numEvents":4}],"term":"Edema"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Rigors"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Fever"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":20,"numEvents":4}],"term":"Dysrhythmia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":20,"numEvents":5}],"term":"Diarrhea"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"C. Diff"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Hematuria"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Cytokine release syndrome"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Encephalopathy"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":20,"numEvents":3}],"term":"Delirium"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":20,"numEvents":2}],"term":"Dysesthesia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Rash maculo-papular"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Mucositis oral"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Central Line"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":3}],"term":"Nausea"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Probably related to pseudo-gout","organSystem":"General disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Edema Limbs"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"GI GVHD"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Liver GVHD"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Skin GVHD"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Diarrhea"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1}],"term":"Platelet count decreased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"NCI CTC 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":2}],"term":"Encephalopathy"}],"timeFrame":"Monitoring of all acute toxicities (grade 3 or higher) occurred until the time of discharge (post-transplant). After discharge, until day 100, only serious toxicities (grade 4 or higher) were recorded. All-Cause Mortality was monitored from the time of transplant to three years post-transplant."}